REVIEW PAPER
Antinuclear antibodies in autoimmune and allergic diseases
Submission date: 2017-11-16
Final revision date: 2017-12-13
Acceptance date: 2017-12-14
Online publication date: 2017-12-30
Publication date: 2017-12-31
Reumatologia 2017;55(6):298-304
KEYWORDS
TOPICS
ABSTRACT
Antinuclear antibodies (ANA) are primarily significant in the diagnosis of systemic connective tissue diseases. The relationship between their occurrence in allergic diseases is poorly documented. However, the mechanism of allergic and autoimmune diseases has a common thread. In both cases, an increased production of IgE antibodies and presence of ANA in selected disease entities is observed. Equally important is the activation of basophils secreting proinflammatory factors and affecting the differentiation of TH17 lymphocytes. Both autoimmune and allergic diseases have complex multi-pathogenesis and often occur in genetically predisposed individuals. The presence of antinuclear antibodies was confirmed in many systemic connective tissue diseases and some allergic diseases. Examples include atopic dermatitis, non-allergic asthma, and pollen allergy. Co-occurring allergic and autoimmune disorders induce further search for mechanisms involved in the aetiopathogenesis of both groups of diseases.
REFERENCES (65)
1.
Szczeklik A, Nizankowska E, Serafin A, et al. Autoimmune Phenomena in Bronchical Asthma with Special References to Aspirin Intolerance. Am J Respir Crit Care Med 1995; 152: 1753-1756.
2.
Nahm DH, Shin MJ, Yim H, et al. Increased levels of circulating autoantibodies to cultured human bronchial epithelial cell in adult patients with nonatopic asthma. J Korean Med Sci 2001; 16: 407-410.
3.
Comi AL, Tedeschi A, Lorini M, et al. Novel clinical and serological aspects in non-allergic asthma. Respir Med 2007; 101: 2526-2533.
4.
Asero R. Chronic idiopathic urticaria: a family study. Ann Allergy Asthma Immunol 2002; 89: 195-196.
5.
Pan Q, Gong L, Xiao H, et al. Basophil Activation-Dependent Autoantibody and Interleukin-17 Production Exacerbate Systemic Lupus Erythematosus. Front Immunol 2017; 27: 348.
6.
Atta AM, Sousa CP, Carvalho EM, et al. Immunoglobulin E and systemic lupus erythematosus. Braz J Med Biol Res 2004; 37: 1497-1501.
7.
Voehringer D. Recent advances in understanding basophil functions in vivo. F1000Res 2017; 6: 1464.
8.
Siracusa MC, KimBS, Spergel JM, et al. Basophils and allergic inflammation. J Allergy Clin Immunol 2013; 132: 788-789.
9.
Ochs RL, Muro Y, Si Y, et al. Autoantibodies to DFS 70 kd/transcription coactivator p 75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000; 105: 1211-1220.
10.
Wakahara K, Baba N, Van V, et al. Human basophils interact with memory T cells to augment Th17 responses. Blood 2012; 120: 4761-4771.
11.
Sharma M, Stephen-Victor E, Poncet P, et al. Basophils are inept at promoting human Th17 responses. Hum Immunol 2015; 76: 176-180.
12.
Asero R, Madonini E.: Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria. J Investig Allergol Clin Immunol 2006; 16: 19-23.
13.
Puszczewicz M, Białkowska-Puszczewicz G, Majewski D. Znaczenie autoprzeciwciał w rozpoznaniu chorób reumatycznych. Postępy Nauk Medycznych 2012; 2: 156-163.
14.
Wiik AS, Hoier-Madsen M, Forslid J, et al. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010; 35: 276-290.
15.
Puszczewicz M. Przeciwciała przeciwjądrowe – cóż z nimi począć? Reumatologia 2013; 51: 172-178.
16.
Tozzoli R, Bonaguri Ch, Melegari A, et al. Current state of diagnostics technologies in the autoimmunology laboratory. Clin Chem Lab Med 2013; 51: 129-138.
17.
Bragazzi NL, Watad A, Adawi M, et al. Adjuvants and Autoimmunity: Why Do We Develop Autoantibodies, Autoimmune Diseases and lymphomas. Israel Med Association J 2017; 19: 403-405.
18.
Wandstrat A, Carr-Johnson F, Branch V, et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006; 27: 153-160.
19.
Li QZ, Karp DR, Quan J, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011; 13: R38.
21.
Fernandez S, Lobo A, Oliveira Z, et al. Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo 2003; 58: 315-319.
22.
Semchuk K, Rosenberg A, McDuffie H, et al. Antinuclear antibodies and bromoxynil exposure in a rural sample. J Toxicol Environ Health A 2007; 70: 638-657.
23.
Bianchi DW, Wataganara T, Lapaire O, et al. Fetal nucleic acids in maternal body fluids. Ann NY Acad Sci 2006; 1075: 63-73.
24.
Grygiel-Górniak B, Puszczewicz MJ. The influence of endogenous and exogenous sex hormones on systemic lupus erythematosus in pre- and postmenopausal women. Prz Menopauzalny 2014; 13: 262-266.
25.
Ishikawa M, Konta T, Hao Z, et al. Relationship between antinuclear antibody and microalbuminuria in the general population: the Takahata study. Clin Exp Nephrol 2008; 12: 200-206.
26.
Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012; 64: 2319-2327.
27.
McGrogan A, Seaman H, Wright J, et al. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol (Oxf) 2008; 69: 687-696.
28.
Vynios DH, Tsagaraki I, Grigoreas GH, et al. Autoantibodies against aggrecan in systemic rheumatic diseases. Biochimie 2006; 88: 767-773.
29.
Ruiz JT, Luján L, Blank M, et al. Adjuvants- and vaccines-induced autoimmunity: animal models. Immunol Res 2017; 65: 55-65.
30.
Watad A, Quaresma M, Bragazzi NL, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld’s syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol 2017; https://doi.org/10.1007/s10067....
31.
Israeli E, Agmon-Levin N, Blank M, et al. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol 2011; 41:163-168.
32.
Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 2014; 48-49: 66-72.
35.
Johansson SG, Bieber T, Dahl R, el al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836.
37.
Szaflarska A, Rutkowska-Zapała M, Kowalczyk D. Krótka charakterystyka mechanizmów tolerancji immunologicznej. Przegląd Lekarski 2015; 72: 765-769.
41.
Rose NR. Molecular mimicry and clonal deletion: A fresh look. J Theor Biol 2015; 375: 71-76.
42.
Manjarrez-Orduno N, Quach TD, Sanz I. B cells and immunological tolerance. J Invest Dermatol 2009; 129: 278-288.
43.
Quintero O, Amador-Patarroyo M, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012; 38: 109-119.
44.
Cutolo M, Straub R. Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther 2009; 11: 218.
45.
Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608.
47.
RNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Faslpr mouse. Proc Natl Acad Sci U S A.
49.
Jackson TA, Haga CL, Ehrhardt GR, et al. FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol 2010; 185: 7405-7412.
50.
O’Neill SK, Getahun A, Gauld SB, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signalling cascade required for B cell anergy. Immunity 2011; 35: 746-756.
51.
Helgason CD, Kalberer CP, Damen JE, et al. A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: Aberrant development and enhanced function of β lymphocytes in ship -/- mice. J Exp Med 2000; 191: 781-794.
52.
Rottem M, Gershwin ME, Shoenfeld Y. Allergic disease and autoimmune effectors pathways. Dcv Immunol 2002; 9: 161-167.
53.
Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract 2014; 2: 645-648.
54.
Ress K, Metsukla K, Annus T, et al. Antinuclear antibodies in atopic dermatitis: a cross sectional study on 346 children. Int J Dermatol 2015; 54: 24-28.
55.
Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immune-fluorescence pattern on Hep-2 cells for the diagnosis of systematic autoimmune diseases. Clin Dev Immunol 2012; 2012: 494356.
56.
Racanelli V, Prete M, Musaraj G, et al. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011; 10: 503-508.
57.
Jabłońska S, Majewski S. Choroby skóry i choroby przenoszone drogą płciową. Wyd. Lekarskie PZWL, Warszawa 2008.
58.
Higashi N, Niimi Y, Aoki M, et al. Clinical features of antinuclear antibody-positive patients with atopic dermatitis. J Nippon Med Sch 2009; 76: 300-307.
59.
Mittermann I, Aichberger KJ, Bünder R, et al. Autoimmunity and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004; 4: 367-371.
60.
Tang TS, Bieber T, Williams HC. Does the autoreactivity play a role in atopic dermatitis? J Allergy Clin Immunol 2012; 129: 1209-1215.
61.
Valenta R, Seiberler S, Natter S, et al. Autoallergy: A pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol 2000; 105: 432-437.
62.
Noack M, Miossec P. Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol 2017; 39: 365-383.
63.
Yoshimoto T, Nakanishi K. Generation and characterization of mouse basophils from bone marrow and purification of basophils from spleen. Curr Protoc Immunol 2012; Chapter 3: Unit 3.24.
64.
Lidor Y, Topilsky M, Spitzer SA, et al. Autoimmune antibodies in intrinsic (non-atopic) asthma. Ann Allergy 1980; 44: 296-298.
65.
Agache I, Duca L, Anghel M. Antinuclear antibodies in asthma patients – a special asthma phenotype? Iran J Allergy Asthma Immunol 2009; 8: 49-52.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
